Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors. 2017

Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
School of Pharmaceutical Sciences & Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou University, Zhengzhou 450001, China.

A new series of [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1 inhibitors were designed, synthesized, and further evaluated for their cytotoxicity against MGC-803, EC109, A549 and PC-9 cells as well as the ability of inhibiting LSD1. Some of these compounds showed potent inhibition toward LSD1 and selectively inhibited growth of A549 and PC-9 cells. Compound 6l potently inhibited growth of PC-9 cells (IC50 = 0.59 μM), about 4-fold more potent than 5-FU. Further SARs studies led to the identification of compounds 6l-m, which had good growth inhibition against all the tested cancer cell lines and were much more potent than 5-FU and GSK2879552. Besides, compounds 5p, 5q and 6i inhibited LSD1 potently (IC50 = 0.154, 1.19 and 0.557 μM, respectively). Docking studies revealed that compound 5p formed arene-H interactions with Val333 and hydrogen bonds with surrounding Ala331, Met332, and Ala539 residues. Compound 5p significantly inhibited migration of A549 and PC-9 cells in a concentration-dependent manner, but had different effect on the expression of E-cadherin and N-cadherin. The [1,2,4]triazolo[1,5-a]pyrimidine scaffold may serve as a starting point for developing potent LSD1 inhibitors for cancer therapy.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
May 2017, Bioorganic & medicinal chemistry letters,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
April 2019, European journal of medicinal chemistry,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
January 2022, European journal of medicinal chemistry,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
December 2022, European journal of medicinal chemistry,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
May 2012, Steroids,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
March 2019, European journal of medicinal chemistry,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
January 2019, Bioorganic & medicinal chemistry letters,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
January 2019, European journal of medicinal chemistry,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
July 2022, Cells,
Shuai Wang, and Li-Jie Zhao, and Yi-Chao Zheng, and Dan-Dan Shen, and Er-Fei Miao, and Xue-Peng Qiao, and Li-Juan Zhao, and Ying Liu, and Ruilei Huang, and Bin Yu, and Hong-Min Liu
June 1998, Journal of medicinal chemistry,
Copied contents to your clipboard!